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Abstract In the European Organisation for Research and
Treatment of Cancer (EORTC)/GMDSSG phase III trial
06011, we compared decitabine (15 mg/m2 every 8 h for
3 days) with best supportive care (BSC) in patients ≥60 years
with myelodysplastic syndromes (MDS) by French-
American-British (FAB) criteria. Here, we reinvestigate trial
06011 for the activity and efficacy specifically in patients with
refractory anemia with excess blasts in transformation
(RAEBt). Response rates in the decitabine arm (N=40) were
as follows: complete or partial remission, 15 %; hematologic
improvement, 15 %; resistant disease, 30 %. RAEBt patients
in the decitabine arm had longer progression-free survival
(PFS; hazard ratio (HR) 0.30, 95 % confidence interval (CI)
0.18–0.51; median, 6.2 vs 2.8 months) and overall survival
(OS; HR 0.68, 95%CI 0.42–1.11; median, 8.0 vs 6.0 months)
than in the BSC arm (N=35). Censoring at allogeneic hema-
topoietic stem cell transplantation, the OS difference between
the treatment groups increased, particularly among patients
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aged 60–74 years (HR 0.48, 95 % CI 0.26–0.89). After
regrouping the study cohort according to World Health Orga-
nization (WHO) criteria, patients with acute myeloid leukemia
(AML) (i.e., ≥20 % blasts) in the decitabine arm (N=27) also
had longer PFS than in the BSC arm (N=23) (HR 0.46, 95 %
CI 0.26–0.83; median, 6.2 vs 2.8 months). In conclusion, 3-
day decitabine displays clinical activity and efficacy in MDS
and/or AML with 5–30 % blood or 20–30 % marrow blasts.
Keywords RAEBt .MDS . AML . Leukemia . Allogeneic
transplantation . Epigenetic therapy
Introduction
Treatment options in patients with myelodysplastic syn-
dromes (MDS) and high blast counts are limited. The median
overall survival (OS) of patients with refractory anemia with
excess blasts in transformation (RAEBt) according to the
French-American-British (FAB) classification is only approx-
imately 6 months, if treated with best supportive care (BSC)
[1, 2], but more intensive therapy is often not feasible due to
older age, poor performance status, or comorbidities [3–5].
Fenaux et a l . showed that t rea tment wi th the
hypomethylating agent azacitidine prolongs OS among older
patients withMDS by FAB criteria and 20–30% bonemarrow
(BM) blasts, compared to BSC [6]. A benefit by the
hypomethylating drug decitabine in such patients has not yet
been established. Among patients with acute myeloid leuke-
mia (AML) according to World Health Organization (WHO)
criteria and 20–30 % BM blasts, Kantarjian et al. observed no
significant improvement of OS by decitabine given at the 5-
day schedule (20 mg/m2 every day for 5 days), compared with
BSC or low-dose cytarabine [7].
In the phase III trial 06011, we compared the 3-day sched-
ule of decitabine (15 mg/m2 every 8 h for 3 days) with BSC in
patients ≥60 years with MDS (FAB) not eligible for intensive
therapy [8]. Decitabine administered at the 3-day schedule for
MDS (FAB) is in line with its approval status in the USA.
In the present analysis, we examine trial 06011 for the
activity and efficacy of decitabine specifically in patients with
MDS (FAB) and higher blast counts (i.e., RAEBt) and in
patients fulfilling the WHO criteria for AML. In both patient
groups, we show an improved outcome in the decitabine com-
pared with the BSC arm.
Patients and methods
Patients
Eligibility criteria of trial 06011 (clinicaltrials.gov Id
NCT00043134) have been previously reported [8] and
included the following: patients ≥60 years old; primary or
treatment-related MDS or chronic myelomonocytic leukemia
(CMML) according to FAB criteria [9]; International Prog-
nostic Scoring System (IPSS) intermediate-1, intermedi-
ate-2, or high risk [1]; BM blasts of 11 to 30 %, or
≤10 % and poor cytogenetics according to IPSS criteria;
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 to 2; and ineligible for intensive che-
motherapy as judged by the treating physician. No pre-
vious treatment with standard chemotherapy or a
hypomethylating agent was allowed. The study was per-
formed in accordance with the Declaration of Helsinki
and approved by the local ethics committees at all par-
ticipating sites. All patients provided written informed
consent.
Study design
Patients were randomly assigned (1:1) to receive either
decitabine and BSC or BSC only. Crossover to the experimen-
tal arm was prohibited. Decitabine (15 mg/m2 in two doses
over 2 h each) was given intravenously every 8 h for 3 days in
6-week cycles [8]. If regeneration of hematologic parameters
was insufficient, the interval between cycles could be extend-
ed up to 10 weeks. Reasons for exit from study were
predefined as disease progression, transformation to AML
(FAB), unacceptable toxicity, or per protocol (i.e., eight
courses of decitabine or ten courses in case complete remis-
sion [CR] was achieved after eight courses).
Endpoints
Primary endpoint was OS (measured from the date of random
assignment until death from any cause or last follow-up (cen-
sored observation)) [8]. Secondary endpoints were AML-free
survival (AMLFS; measured from the date of random assign-
ment to transformation to AML [FAB] or death from any
cause, whichever occurred first), progression-free survival
(PFS; measured from the date of random assignment to pro-
gression, relapse after achievement of CR or partial response
[PR], or death, whichever occurred first), and best response
rate. Responses were assessed according to International
Working Group criteria for MDS defined by the FAB classi-
fication [10]. BM examinations were planned after every other
cycle of decitabine and at weeks 24 and 48 in the BSC arm, or
earlier in both arms if progression was suspected. Blood
smears, BM aspirates and biopsies, and cytogenetics were
centrally reviewed.
Statistical analyses
Survival estimates were calculated using the Kaplan-Meier
method; standard errors of the estimates were obtained via
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the Greenwood formula [11]. The two-sided, log-rank test
evaluated differences between survival distributions. The
Cox proportional hazards model was used to obtain hazard
ratio (HR) estimates and corresponding confidence intervals
(CIs). Subgroup analyses were performed using Forest plot
techniques [12]. For main efficacy analyses, the intent-to-
treat principle was followed. As sensitivity analysis for OS
comparison, the follow-up was censored at time of allogeneic
hematopoietic stem cell transplantation (alloHSCT). The da-
tabase was located at the European Organisation for Research
and Treatment of Cancer (EORTC) Headquarters, and all anal-
yses were performed using SAS software (version 9.3 and 9.4,
SAS Institute, Cary, NC, USA).
Results
Characteristics of the patients with RAEBt
From October 2002 through May 2007, 233 patients from 40
centers in nine European countries were randomly assigned to
receive decitabine (N=119) or BSC (N=114) within trial
06011. Among the 233 patients, 75 patients were diagnosed
with RAEBt and 125 with RAEB. The remaining 33 patients
had refractory anemia (RA), refractory anemia with ring
sideroblasts (RARS), CMML, or AML by FAB criteria.
Of the 75 RAEBt patients, 40 were randomized into the
decitabine and 35 into the BSC arm (Fig. 1). The treatment
arms were well balanced. The median age was similar in both
treatment groups, i.e., 69.5 years in the decitabine and 69 years
in the BSC arm. Patients in the decitabine arm tended to more
often have WBC less than 2.5×109/L and good- or
intermediate-risk cytogenetics according to IPSS criteria, but
there were no differences for sex, ECOG performance status,
or IPSS risk (Table 1).
With regard to the blast counts, 19 (47.5 %) of the RAEBt
patients in the decitabine arm and 18 (51.4 %) of those in the
BSC arm had 21% ormore BMblasts. The remaining patients
were classified as having RAEBt based on the presence of 5–
30 % blasts in the peripheral blood or of Auer rods.
The median number of decitabine courses administered to
the RAEBt patients was 2.5 (mean, 3.9; range 0–10), which
equals approximately 4 months of treatment. Two (5 %) pa-
tients did not receive the study drug, 10 % received one
course, 35 % two courses, 27.5 % three to six courses, and
22.5 % eight or more courses.
Outcome among the patients with RAEBt
Among the RAEBt patients in the decitabine arm, 30 %
reached either CR (10 %), PR (5 %), or hematologic improve-
ment (HI; 15 %); stable disease (SD) occurred in 30 %, and in
another 30 %, the disease was primarily progressive. In the
BSC arm, no patient achieved CR, PR, or HI; 14.3 % of the
patients experienced a period of SD, and 80 % directly went
into PD (Table 2).
The favorable response rates of the RAEBt patients in the
decitabine arm translated into a PFS that was highly signifi-
cantly longer than that of patients under BSC (P<0.001;
Table 2, Fig. 2a). The risk of PD, relapse, or death among
RAEBt patients in the decitabine arm was only 30 % of that
of RAEBt patients under BSC (Table 2). RAEBt patients in
the decitabine arm also had a significantly improved AMLFS,
compared with patients in the BSC arm (P=0.003) (Fig. 2b).
In addition to the significant improvements in PFS and
AMLFS, RAEBt patients in the decitabine arm had a,
Assessed for eligibility, n=75
Allocated to best supportive care, n=35
Started allocated intervention, n=35
Did not receive allocated intervention, n=0
Allocated to decitabine, n=40
Started allocated intervention, n=38
Did not receive allocated intervention, n=2
Randomly allocated, n=75
Lost to follow-up, n=0
Normal completion of study protocol, n=0
Discontinued intervention, n=35
Progressive disease, n=18
Toxicity, n=0
Hypoplasia, n=0
Death, n=9
Refusal of the patient, n=4
Protocol violation, n=2
Ineligibility, n=0
Other, n=2
Analyzed, n=35
Lost to follow-up, n=0
Normal completion of study protocol, n=11
Discontinued intervention, n=29
Progressive disease, n=15
Toxicity, n=4
Hypoplasia, n=0
Death, n=5
Refusal of the patient, n=2
Protocol violation, n=2
Ineligibility, n=0
Other, n=1
Analyzed, n=40
Fig. 1 CONSORT diagram
considering the patients with
RAEBt in trial 06011. A
CONSORT diagram considering
the entire cohort is provided
elsewhere [8]
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although not significant (P=0.12), prolongation of their me-
dian OS (8.0 vs 6.0 months) (Table 2, Fig. 2c). As post-pro-
gression treatment, particularly in the form of potentially cu-
rative alloHSCT, may influence OS, we censored the survival
of the two patients in the decitabine and five patients in the
BSC arm, who received an alloHSCT, at the time of HSCT.
We observed that the difference in the OS between the two
treatment groups slightly increased in favor of those RAEBt
patients treated in the decitabine arm (P=0.07) (Table 2,
Fig. 3a).
All RAEBt patients who received an alloHSCT were 60–
74 years old. We restricted further exploratory OS analyses to
this age group, i.e., to patients who, as defined by age, are
potential candidates for an alloHSCT following reduced in-
tensity conditioning.Within this age group and censored at the
time of alloHSCT, RAEBt patients in the decitabine arm had
longer OS than those in the BSC arm (P=0.018) (Table 2,
Fig. 3b).
Outcome comparisons between patients with RAEBt vs
RAEB
In our initial report on the entire study cohort of trial
06011, we observed a significantly longer PFS for pa-
tients in the decitabine arm, but no significant differences
regarding AMLFS or OS between the treatment arms [8].
Thus, we wondered how the results of the present anal-
yses in RAEBt patients compared to the results in other
FAB subgroups. Since patient numbers were too small
for conclusive analyses in RA (N=5 in the decitabine
arm, N=8 in the BSC arm), RARS (N=3, N=2), and
CMML (N=10, N=4), we focused on the treatment com-
parison in RAEBt and RAEB patients (Fig. 4a–c). We
observed that the effect of decitabine on both PFS and
AMLFS was significantly greater among the RAEBt than
RAEB patients (tests for heterogeneity, P=0.0001 and
P=0.004, respectively). With regard to OS, the impact
of decitabine vs BSC was also stronger in the RAEBt
than the RAEB patients, although the difference did not
reach statistical significance (test for heterogeneity, P=
0.07).
Survival in subgroups of RAEBt patients
We further explored whether the positive impact of
decitabine can be observed in subgroups of RAEBt pa-
tients defined by age, BM blasts, IPSS risk, or time
from diagnosis (Fig. 5, Supplementary Fig. S1). With
regard to PFS, AMLFS, and OS, there were no signif-
icant differences in the effect of decitabine among the
various subgroups.
Table 1 Pretreatment features of patients with RAEBt
Feature RAEBt
Decitabine (N=40) BSC (N=35)
Age (years)
Median 69.5 69
Range 61–90 61–80
Age (years), N (%)
60–64 10 (25.0) 6 (17.1)
65–69 10 (25.0) 12 (34.3)
70–74 8 (20.0) 10 (28.6)
≥75 12 (30.0) 7 (20.0)
Sex, N (%)
Male 29 (72.5) 24 (68.6)
Female 11 (27.5) 11 (31.4)
ECOG performance status, N (%)
0 8 (20.0) 10 (28.6)
1 29 (72.5) 19 (54.3)
2 3 (7.5) 6 (17.1)
WBC, ×109/L
<2.5 20 (50.0) 11 (31.4)
2.5−<10 11 (27.5) 18 (51.4)
≥10 8 (20.0) 6 (17.1)
%BM blasts, N (%)
≤20 % 21 (52.5) 17 (18.6)
21–30 %a 19 (47.5) 18 (51.4)
Disease status
Primary, untreated 8 (20.0) 1 (2.9)
Primary, pretreatedb 28 (70.0) 31 (88.6)
Secondary 4 (10.0) 3 (8.6)
Cytogenetic risk (IPSS), N (%)
Good 16 (40.0) 5 (14.3)
Intermediate 4 (10.0) 5 (14.3)
Poor 14 (35.0) 17 (48.6)
Failed 5 (12.5) 8 (22.9)
Not assessed 1 (2.5) 0 (0.0)
IPSS, N (%)
Intermediate 1 2 (5.0) 0 (0.0)
Intermediate 2 12 (30.0) 13 (37.1)
High risk 26 (65.0) 22 (62.9)
Time from diagnosis to random assignment (months), N (%)
≥3 16 (40.0) 20 (57.1)
<3 24 (60.0) 15 (42.9)
RAEBt refractory anemia with excess blasts in transformation, BSC best
supportive care, BM bonemarrow, ECOG Eastern Cooperative Oncology
Group, IPSS International Prognostic Scoring System
a Includes one patient with 40 % BM blasts
b For example, with transfusions, hydroxyurea, growth factors, immuno-
suppressive therapy
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Characteristics and outcome of patients with AML
according to WHO
Patients with 20–30 % blasts in blood or BM have RAEB or
RAEBt according to the FAB classification, but AML accord-
ing to the WHO [9, 13]. As the FAB classification is widely
replaced by the WHO classification, we also investigated trial
06011 after regrouping the patients according to WHO
criteria.
We identified 50 patients with AML and 20–30 % blasts in
BM (N=49) or blood (N=1). Patients not diagnosed with
AML and 20–30 % blasts were combined into the group of
patients withMDS according toWHO (N=164) or were those
with CMML, BM blasts >30 %, or no blast counts available.
Of the AML patients, 27 were in the decitabine and 23 in the
BSC arm (Supplementary Fig. S2). The median age was
70 years in both arms, and there were no major differences
for sex, ECOG performance status, WBC, FAB subtype, cy-
togenetic risk, IPSS risk, and time from diagnosis to treatment
assignment (Supplementary Table S1). A median of three
courses was administered in the decitabine arm (mean 3.9,
range 0–8); 37 % of the patients received one to two courses,
18.5 % each three courses or four to six courses, and 22.2 %
received all eight courses of the study protocol.
In the decitabine arm, 33.3% of the AML patients achieved
CR (11.1 %), PR (11.1 %), or HI (11.1 %), and 37 %
progressed directly; in the BSC arm, no patient achieved
CR, PR, or HI, and 73.9 % of the patients had PD
(Supplementary Table S2). AML patients in the decitabine
arm had a significantly longer PFS than those in the BSC
arm (P=0.008; Supplementary Table S2, Supplementary
Fig. S3). However, this did not translate into a significantly
improved OS of the patients in the decitabine arm, although
the median OS was 9.8 months, compared to 5.9 months in
patients receiving BSC only (Supplementary Table S2,
Supplementary Fig. S3). When censored at the time of
alloHSCT, the OS difference also did not reach statistical sig-
nificance (Supplementary Table S2).
Table 2 Treatment response of
patients with RAEBt Outcome endpoint RAEBt
Decitabine (N=40) BSC (N=35) HR (95 % CI) P valuea
Best response, N (%)
Complete remission 4 (10.0) 0 (0.0) n.a. n.a.
Partial remission 2 (5.0) 0 (0.0)
Hematologic improvement 6 (15.0) 0 (0.0)
Stable disease 12 (30.0) 5 (14.3)
Progressive disease 12 (30.0) 28 (80.0)
Hypoplasia 2 (5.0) 0 (0.0)
Not evaluable 2 (5.0) 2 (5.7)
Progression-free survival
Median (months) 6.2 2.8 0.30 (0.18–0.51) <0.001
% at 6 months 50.0 20.0
AML (FAB)-free survival
Median (months) 7.0 3.7 0.49 (0.30–0.80) 0.003
% at 6 months 52.5 31.4
Overall survival
Median (months) 8.0 6.0 0.68 (0.42–1.11) 0.12
% at 6 months 65.0 51.4
Overall survival, censored at time of alloHSCT
Median (months) 8.0 5.9 0.63 (0.38–1.04) 0.07
% at 6 months 66.7 48.1
Overall survival, censored at time of alloHSCT, 60–74 yearsb
Median (months) 8.0 5.8 0.48 (0.26–0.89) 0.018
% at 6 months 63.1 41.2
RAEBt refractory anemia with excess blasts in transformation, BSC best supportive care, HR hazard ratio, CI
confidence interval, n.a. not applicable, AML acute myeloid leukemia, FAB French American British classifica-
tion, alloHSCT allogeneic hematopoietic stem cell transplantation,
a Two-tailed log-rank test
b Subgroup of patients aged 60–74 years: decitabine arm, N=28; BSC arm, N=28
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Fig. 2 a Progression-free
survival, b AML (FAB)-free
survival, and c overall survival of
RAEBt patients treated with
decitabine or best supportive care
(BSC). Further details are
provided in Table 2
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Discussion
In patients with MDS and high blast counts, if ineligible for
intensive therapy, decitabine and azacitidine have become
standard of care. Fenaux et al. observed that older patients
with MDS (FAB) and 20–30 % BM blasts who received
azacitidine had longer OS than those receiving BSC only
[6]. Such an effect of azacitidine had been also suggested in
a previous pooled analysis of various studies [14]. A compa-
rable effect of decitabine in this patient group has not yet been
established.
Decitabine given at the 5-day schedule is approved in Eu-
rope for use in AML (WHO) in patients ≥65 years not eligible
for standard chemotherapy. In these patients, 5-day decitabine
resulted in trends for a longer OS than treatment with BSC
only or, more often, combined with low-dose cytarabine [7].
In subgroup analyses, no significant impact of decitabine on
OS among patients with 20–30 % BM blasts was observed,
although the median OS was prolonged by approximately
2 months in the decitabine arm (8.0 vs 6.1 months); no data
on other survival endpoints were presented [7].
Decitabine at the 3-day schedule (in addition to the 5-day
schedule) is approved in the USA for the treatment of MDS of
all FAB subtypes, with a recommended duration of 3 h per
infusion instead of 4 h as in our study. Kantarjian et al. ob-
served that patients with MDS (FAB) receiving 3-day
decitabine had a, by trend, longer AMLFS than with BSC
[15]. In post hoc analyses, data from this study were combined
(months)
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Logrank test: p=0.07
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Fig. 3 Overall survival censored
at the time of allogeneic
hematopoietic stem cell
transplantation of RAEBt patients
treated with decitabine or best
supportive care (BSC)
considering a the entire cohort or
b patients aged 60–74 years.
Further details are provided in
Table 2
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with those of another trial, in which MDS (FAB) patients
received 5-day decitabine [16, 17]. Here, decitabine did not
prolong the OS of patients with BM blasts ≥20 % (89 % had
20–30%BMblasts) to that of patients withMDS and less BM
blasts [17].
In our phase III trial 06011, patients withMDS (FAB) were
randomized to decitabine at the 3-day schedule or BSC only.
As previously published [8], in the entire cohort, patients in
the decitabine arm had longer PFS but similar OS compared
with those in the BSC arm. For the present analysis, trial
a
b
c
Fig. 4 Forest plots displaying a
progression-free survival, b AML
(FAB)-free survival, and c overall
survival of patients with RAEBt
or RAEB. DAC decitabine, BSC
best supportive care, O−E
observed minus expected number
of events, Var variance, HR
hazard ratio, CI confidence
interval, FAB French-American-
British classification assessed by
the study coordinators (SC)
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06011 gave us the opportunity to evaluate decitabine specifi-
cally among patients with RAEBt or AML (WHO) with low
blast counts. Although the cohorts of RAEBt and AML
(WHO) patients overlap, we decided to investigate both
groups since the original study population was defined by
FAB criteria, but the WHO classification is the one more
widely used nowadays.
Among the RAEBt patients, those in the decitabine arm
had, as expected, more favorable responses than those in the
BSC arm. This is probably best reflected by the rates of pa-
tients whose disease was primarily progressive, which were
30% in the decitabine and 80% in the BSC arm. Accordingly,
we observed a highly significant prolongation of PFS and
AMLFS in the decitabine arm, and patients in the decitabine
arm also tended to have a longer OS (median, 8.0 vs
6.0 months). While the median OS in our study appears short
in comparison with that reported by Fenaux et al. from the
comparison of azacitidine and BSC only (median, 19.1 vs
13.4 months), the studies are not directly comparable due to
differences in the patient cohorts, as displayed by the OS of
patients in the BSC arms [6]. The few retrospective studies
that compared decitabine and azacitidine did not specifically
assess the survival among patients with RAEBt and/or 20–
30 % blasts [18–22]. Importantly, we also observed that the
favorable impact of decitabine on the outcome of RAEBt
patients was similar among various patient subgroups and
significantly differed from that among RAEB patients.
Observing the strong impact of decitabine on PFS and
AMLFS compared with the weaker effect on OS, we won-
dered whether this could be due to the treatment that patients
received after being off-study. Among such treatments, an
alloHSCT has the potential to cure from the disease and pro-
long survival. Indeed, when censoring at the time of
alloHSCT, the benefit of decitabine on OS among RAEBt
patients became more evident. This was particularly true for
patients aged 60–74 years, thus for patients who are potential
candidates for alloHSCT after reduced intensity conditioning.
When we regrouped the patients according to WHO
criteria, patients with AML also had a longer PFS in the
decitabine than in the BSC arm. However, in accordance to
the observations in patients with 20–30 % BM blasts using 5-
day decitabine [7], the difference in OS between the
decitabine and BSC arms was not significant.
The effect of decitabine on the survival endpoints in pa-
tients with AML (WHO) appeared weaker than in RAEBt
patients. This difference may be explained by the following:
Approximately half of the RAEBt patients were not included
in the AML (WHO) cohort, as they did not have blast counts
of 20–30 %; several RAEB patients were included in the
AML (WHO) cohort, and decitabine had no impact on the
Fig. 5 Forest plot displaying
progression-free survival of
patients with RAEBt. The
following factors were analyzed:
patient age, bone marrow (BM)
blasts, risk according to
International Prognostic Scoring
System (IPSS), and time from
diagnosis to treatment
assignment.DAC decitabine, BSC
best supportive care, O−E
observed minus expected number
of events, Var variance, HR
hazard ratio, CI confidence
interval, INT-1 intermediate-1
risk, INT-2 intermediate-2 risk,
HR high risk
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survival endpoints among RAEB patients; the cohort of pa-
tients with AML (WHO) was relatively small.
Despite our result of a strong and favorable impact of 3-day
decitabine in RAEBt rather than AML (WHO) with low blast
counts, it would probably be misleading to conclude that 3-
day decitabine is solely effective in patients who strictly fulfill
the FAB criteria of RAEBt, as opposed to those who have
AML according to the WHO classification, considering the
overlapping clinical and biologic features. It remains, howev-
er, elusive to what extent our findings can be transferred to
patients with AML and >30 % blasts, particularly since the
AML cases in our analyses are probably best represented by
the WHO category of AML with myelodysplasia-related
changes [23].
In patients ≥65 years with AML and >30 % BM blasts
(32 % of patients had AML with myelodysplasia-related
changes), Dombret et al. compared azacitidine vs convention-
al care. They observed that patients in the azacitidine arm had
longer OS than those in the BSC arm (median, 5.8 vs
3.7 months) [24]. In the previously mentioned study by
Kantarjian et al., patients ≥65 years with AML and >30 %
BM blasts receiving 5-day decitabine also had a significantly
longer OS than those receiving low-dose cytarabine (88 % of
patients) or BSC (12 %) (median, 7.1 vs 4.3 months) [7].
Considering the effect of decitabine among RAEBt patients
in our study, it would have been of interest to know whether
this correlates with the presence of certain genetic or epige-
netic features of RAEBt and whether such features could pre-
dict the response to decitabine. Studies have suggested asso-
ciations between the response to decitabine and genetic aber-
rations (e.g., monosomal karyotype, TET2mutations), mRNA
or microRNA expression, or DNA methylation [25–32]. Un-
fortunately, we did not have sufficient material to investigate
molecular markers in our cohort. However, we are studying
the predictive value of a monosomal karyotype for decitabine
treatment in MDS (manuscript in preparation).
It remains to be established whether decitabine given at the
5-day schedule in RAEBt would resemble our results using
the 3-day schedule. Due to the three infusions per day, the 3-
day schedule is not feasible in the outpatient setting. However,
it is a valid option for patients hospitalized for or during treat-
ment (e.g., due to poor performance status or long distance to
the treatment center), and the more continuous application of
decitabine in the 3-day schedule is supported by its relatively
short plasma half-life [33].
In addition to the potential prolongation of OS, the positive
effect on PFS and AMLFS among RAEBt patients may be
used as bridge to alloHSCT, as the patient’s general condition
may improve under therapy. In older patients with AML, who
are eligible for intensive chemotherapy, we currently perform
a prospective trial of alloHSCT following the intensified 10-
day schedule of decitabine or a standard chemotherapy regi-
men (ClinicalTrials.gov Id NCT02172872).
Since the number of decitabine cycles was restricted to a
maximum of 8 (or 10 in case that the patient achieved CR) in
our study, we could not examine how a prolonged treatment
with decitabine would have affected the survival endpoints.
However, current data suggest that the hypomethylating ther-
apy should be continued after achievement of a sustained re-
sponse [34]. Maintenance therapy using hypomethylating
agents may also be particularly effective in the post-
alloHSCT setting [35, 36].
In conclusion, our data point to the clinically relevant effi-
cacy of decitabine using the 3-day schedule in patients with
RAEBt and AML (WHO) with low blast counts, particularly
by delaying progression or relapse, and, in case of RAEBt,
also death.
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